Currency in CHF
Last close As at 25/01/2023
— 0.00 (13.33%)
Based in Switzerland, Kinarus Therapeutics is a clinical-stage pharmaceutical company focused on advancing lead candidate KIN001 in inflammatory, fibrotic and/or viral infection-related conditions.
Upon availability of new funding, Kinarus plans to start a Phase II study in wet AMD, backed by preclinical data suggesting potential benefit in reducing choroidal neovascularisation lesions. Having shown in vitro antiviral activity against many COVID-19 variants, KIN001 is currently being assessed in the KINFAST Phase II study in ambulatory COVID-19 patients.
|52 week high/low||CHF0.1/CHF0.0|
Kinarus Therapeutics is advancing KIN001, a patented orally dosed combination of p38 mitogen-activated protein kinase inhibitor pamapimod and pioglitazone. Preclinical data suggest this combination may have anti-inflammatory and anti-fibrotic activity, as well as antiviral properties against COVID-19. KIN001 is under development for the treatment of wet age-related macular degeneration (wet AMD), its lead indication, as well as idiopathic pulmonary fibrosis and COVID-19. Wet AMD is a leading cause of vision loss in older adults and there are no oral drugs approved to treat the condition, signalling a potentially significant unmet need.
|Y/E Dec||Revenue (CHFm)||EBITDA (CHFm)||PBT (CHFm)||EPS (fd) (CHFc)||P/E (x)||P/CF (x)|